By Kunal Das
March 31 (Reuters) – Biotech firm Infinimmune said on Tuesday it has entered into a deal with drugmaker Merck that could be worth up to about $838 million in milestone payments, to discover and develop multiple antibodies for various undisclosed diseases.
(Reporting by Kunal Das in Bengaluru; Editing by Shailesh Kuber and Sahal Muhammed)
Comments